Almost one million people have taken an experimental coronavirus vaccine developed by China National Pharmaceutical Group (Sinopharm) through the country's emergency use programme, the firm said late on Wednesday.
"In terms of emergency use, the vaccines were applied to almost a million people and there has not been a single case of a serious adverse event".
Sinopharm's unit China National Biotec Group (CNBG) has moved two vaccine candidates into Phase 3 clinical trials outside China in multiple countries including the United Arab Emirates, Bahrain, and Egypt involving more than 50,000 participants in total. The data from an emergency program is inefficient and unable to determine a vaccine's effectiveness.
No serious adverse reaction has been reported from those who received the vaccine in emergency use, Sinopharm said in an article on social media WeChat, citing Chairman Liu Jingzhen from a recent media interview.
"The robust antibody and T-cell responses seen in older people in our study are encouraging", said Maheshi Ramasamy, a consultant and co-lead investigator at the Oxford Vaccine Group.
The vaccine is now undergoing a three phase clinical trial overseas with 60,000 participants.
Two other drugmakers, Pfizer and Moderna, this week reported preliminary results from late-stage trials showing that their COVID-19 vaccines were nearly 95% effective. Even after vaccines are approved by regulators, drugmakers and public health officials still face the task of producing billions of doses and administering them to people around the world, he said.
Pharmaceutical companies around the world have been working on a COVID-19 vaccine since the early stages of the pandemic.
Since the announcement by the American company Pfizer to make 95 percent effective corona vaccine, many countries have claimed to make effective vaccine.
The Chinese company has not yet provided any clear clinical evidence of efficacy.
Meanwhile, the Lancet Infectious Diseases journal said that a Chinese inactivated COVID-19 vaccine candidate has been proved safe and tolerable and can induce a quick immune response.
Unlike the Pfizer-BioNTech and Moderna shots, both of which use new technology known as messenger RNA (mRNA), AstraZeneca's is a viral vector vaccine made from a weakened version of a common cold virus found in chimpanzees. Demand is clearly high, and several wealthy nations already have their pre-orders in place.